Financial Data and Key Metrics Changes - VITAS net revenue for Q4 2020 was $332 million, a decline of 2.3% compared to the prior year period [17] - Average revenue per patient per day in Q4 2020 was $198.33, which is 7 basis points below the prior year period [18] - Roto-Rooter generated revenue of $201 million in Q4 2020, an increase of 10.2% [21] - Consolidated revenue, including Roto-Rooter, increased by 10.2% [16] Business Line Data and Key Metrics Changes - VITAS admissions increased by 2.8% in Q4 2020, but average daily census declined by 2.8% [8][9] - Roto-Rooter’s residential revenue totaled $123 million in Q4 2020, an increase of 20.8% [14] - Nursing home admissions for VITAS decreased by 19.3% in Q4 2020 compared to the prior year [11] Market Data and Key Metrics Changes - Hospital referrals for VITAS returned to pre-pandemic levels, with hospital-generated admissions increasing by 7.4% in Q4 2020 [11] - Senior housing occupancy levels reached a record low in October 2020, adversely affecting VITAS nursing home admissions [12][25] Company Strategy and Development Direction - The company anticipates improvement in senior housing admissions in the second half of 2021 as occupancy returns to pre-pandemic levels [13][26] - Roto-Rooter is forecasted to achieve revenue growth of approximately 5% to 6% in 2021 [27] - The company plans to continue pursuing share buybacks throughout 2021 [49] Management Comments on Operating Environment and Future Outlook - Management noted that the pandemic has materially disrupted the healthcare system and general economy, impacting guidance for 2021 [24] - There is optimism regarding vaccination rates and their potential impact on nursing home occupancy and admissions [45][47] - Management expects that the normalization of admission patterns will take time, potentially extending into 2022 [36] Other Important Information - VITAS anticipates a decline in revenue of approximately 4% for 2021 compared to the prior year [26] - The adjusted EBITDA margin for VITAS is estimated to be 19.4% for 2021, which is above pre-pandemic levels [27] Q&A Session Summary Question: Guidance and recovery in admission patterns - Management indicated that the pace of improvement in admission patterns is uncertain and may take until the end of 2021 or into 2022 to normalize [35][36] Question: Changes in vaccination rates and their impact - Management noted encouraging signs related to vaccination rates and their potential positive impact on nursing home admissions [45][47] Question: Margin sustainability for VITAS and Roto-Rooter - Management confirmed that the adjusted EBITDA margin for VITAS is expected to remain above 19%, while Roto-Rooter’s margin is projected to be sustainable at 26% [68][70]

45202 (Zipcode) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2020 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 31-0791746 (State or other jurisdiction of incorporation or org ...

Financial Data and Key Metrics Changes - Chemed Corporation reported a net revenue of $337 million for VITAS in Q3 2020, representing a 4.8% increase compared to the prior year period [17] - Roto-Rooter generated quarterly revenue of $191 million in Q3 2020, an increase of $32.3 million or 20.4% over the prior year [22] - Adjusted EBITDA for VITAS, excluding Medicare Cap, totaled $68.2 million, a 25.6% increase, with an adjusted EBITDA margin of 20.5%, reflecting a 367 basis point improvement [21] Business Line Data and Key Metrics Changes - VITAS' average revenue per patient per day was $194.10, which is 3.2% above the prior year period [18] - Roto-Rooter’s residential revenue increased by 24.6%, while commercial revenue declined by 11.6% in Q3 2020 [15][23] - Total admissions for VITAS were 17,943, a 4.7% increase compared to Q3 2019, with home-based pre-admit patients increasing by 18.3% [31] Market Data and Key Metrics Changes - Roto-Rooter’s unit-for-unit commercial revenue declined 11.6% compared to the prior year quarter, but showed significant improvement from a 29.1% decline in Q2 2020 [13] - The average daily census for VITAS was 19,045 patients, a slight decline of 0.2% over the prior year [29] - The average length of stay for VITAS patients increased to 97.1 days compared to 92.6 days in Q3 2019 [32] Company Strategy and Development Direction - Chemed Corporation maintained full staffing and operating capacity for Roto-Rooter during the pandemic to capitalize on potential demand recovery [12] - The company anticipates continued strong operational and financial results for both VITAS and Roto-Rooter as they navigate the pandemic [16] - Chemed is focusing on maintaining a diverse referral stream to ensure a steady flow of patients across various healthcare settings [47] Management's Comments on Operating Environment and Future Outlook - Management noted that the pandemic has disrupted traditional admission patterns, but improvements have been observed in the third quarter [10][30] - The company expects a normalization of admissions as nursing homes and assisted-living facilities return to pre-COVID occupancy levels [11] - Future guidance for VITAS indicates a revenue growth estimate of 4% for 2020, with an average daily census expected to expand approximately 1.3% [26] Other Important Information - Chemed's full-year 2020 adjusted earnings per diluted share is estimated to be in the range of $18 to $18.15, compared to $13.95 in 2019 [27] - The company has utilized over $150 million for share repurchases in the first nine months of the year, targeting about $200 million for the full year [68] Q&A Session Summary Question: Impact of nursing homes and assisted-living facilities on VITAS - Management indicated that nursing homes account for about 14% of VITAS' census, and while there has been a decline, they do not heavily depend on this segment [38] Question: Expectations for ADC normalization - Management expressed uncertainty about when patient flow into nursing homes will return to pre-pandemic levels, but noted potential pent-up demand [41] Question: Revenue guidance for VITAS in Q4 - Management anticipates sequential revenue growth from Q3 to Q4, but a slight decline compared to the prior year due to acuity mix shifts [44] Question: Sustainability of VITAS margins - Management acknowledged that while margins may be impacted by the return of sequestration, effective use of telehealth is expected to remain a positive factor [49] Question: Roto-Rooter margin sustainability - Management believes Roto-Rooter will maintain strong margins due to high residential demand and improving commercial activity [56]

| --- | --- | --- | |----------------------------------|-------|-------| | | | | | | | | | | | | | CHEMED CORPORATION | | | | | | | | | | | | Results as of September 30, 2020 | | | | | | | | | | care | Safe Harbor and Regulation G Statement This presentation contains information about Chemed's EBITDA, Adjusted EBITDA, EBIT, Adjusted EBIT, Adjusted Net Income and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Cheme ...

Chemed Corporation (NYSE:CHE) Q2 2020 Earnings Conference Call July 30, 2020 10:00 AM ET Company Participants Sherri Warner - Investor Relations Kevin McNamara - President & Chief Executive Officer David Williams - Executive Vice President & Chief Financial Officer Nicholas Westfall - Executive Vice President, Chief Executive Officer & Chief Operating Officer, VITAS Healthcare Corporation Conference Call Participants Bradley Bowers - Bank of America Merrill Lynch Frank Morgan - RBC Capital Markets Operator ...

| --- | --- | |------------|---------------------| | | | | Employer | Identification No.) | | 45202 (Zip | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2020 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as specified ...

| --- | --- | --- | |-----------------------------|--------------------|-------| | | | | | | | | | | CHEMED CORPORATION | | | | | | | Results as of June 30, 2020 | | | | | | | | | | | | | | care | Safe Harbor and Regulation G Statement This presentation contains information about Chemed's EBITDA, Adjusted EBITDA, EBIT, Adjusted EBIT, Adjusted Net Income and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed's f ...

| --- | --- | --- | --- | |------------------------------|--------------------|-------|-------| | | | | | | | | | | | | CHEMED CORPORATION | | | | | | | | | Results as of March 31, 2020 | | | | | | | | | | | | | | | | Healtr | | care | Safe Harbor and Regulation G Statement This presentation contains information about Chemed's EBITDA, Adjusted EBITDA, EBIT, Adjusted EBIT, Adjusted Net Income and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that ar ...

| --- | --- | |-------|------------------------------------| | | | | (IRS | Employer Identification No.) 45202 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2020 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as speci ...

Chemed Corporation (NYSE:CHE) Q1 2020 Results Earnings Conference Call April 29, 2020 10:00 AM ET Company Participants Sherri Warner - Investor Relations Kevin McNamara - President and Chief Executive Officer David Williams - Executive Vice President and Chief Financial Officer Nicholas Westfall - Executive Vice President; and Chief Executive Officer and Chief Operating Officer, VITAS Healthcare Corporation Conference Call Participants Bradley Bowers - Bank of America Merrill Lynch Frank Morgan - RBC Capita ...